Krista Kauppinen

Krista Kauppinen has worked at various companies since 2006. From 2006 to 2008, they were a Postdoctoral Associate at Cornell University, where they conducted epigenetics research. In 2008, they were an IP Intern at Affymetrix, Inc. In 2009, they were a Summer Associate in the Patents and Innovation Strategies Group at Wilson Sonsini Goodrich & Rosati, as well as a Patent Prosecution Consultant for various biotech clients. From 2013 to 2016, they were a Patent Agent at BioTime, Inc. (now Lineage Cell Therapeutics, Inc.), where they were the sole in-house practitioner responsible for the collective patent portfolio of BioTime, Inc. and five of its subsidiaries, including Asterias Biotherapeutics, Inc. From 2016 to 2019, they were Senior Director, Intellectual Property and Director, Intellectual Property at Asterias Biotherapeutics, where they were responsible for all patent prosecution, inbound and outbound IP licensing matters and overall IP strategy for a clinical stage cell therapy company with a global 450+ patent portfolio. Since 2019, they have been Vice President, Legal Affairs and Practice Expert, Intellectual Property and Practice Expert, Intellectual Property at Dark Horse Consulting Group Inc. In 2022, they will become Associate General Counsel and Head, Intellectual Property at Clade Therapeutics.

Krista Kauppinen obtained their B.S. (Honors) from Cornell University between 1995 and 1999. Krista then went on to pursue a Ph.D. from Cornell University, which they completed in 2006. In 2007, they obtained their J.D. from the University of California, Davis. Krista is also admitted to the State Bar of California and registered to practice before the USPTO.